The Immune Landscape of Epithelial Ovarian Cancer
Key facts
- Where
- Bellinzona, SwitzerlandSee the site
Where in Switzerland
- Oncology Institute of Southern SwitzerlandBellinzona, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oncology Institute of Southern Switzerland
- Trial code
- NCT05984875
- Record updated
- 18 November 2025
- Original description
This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC).Read full original descriptionShow less
The Immune Landscape of Epithelial Ovarian Cancer: a Prospective Observational Study
This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC).
Patients with newly diagnosed epithelial OC will be enrolled in 4 different cohorts: A) Newly diagnosed high grade serous or endometroid OC undergoing primary debulking surgery; B) Newly diagnosed high grade serous or endometroid OC undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery; C) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing primary debulking surgery; D) Rare subtypes of epithelial OC (low grade serous, low grade endometrioid, clear cell, mucinous or carcinosarcoma) undergoing NACT followed by interval debulking surgery. A cohort of women undergoing adnexectomy for benign pathology will be enrolled (cohort E) for comparative analysis.
Enrolled patients will be asked to provide the following biological samples at specified time points: archival and fresh tumor tissue, peripheral blood samples, rectal and vaginal swabs, ascites (when present).
The main aim of the study is to characterize the immune landscape of epithelial OC in tumor tissue and peripheral blood and correlate the presence of myeloid-derived suppressive cells (MDSCs) and other immune infiltrates and of the systemic immune response with progression free interval (PFI) in epithelial OC.
Inclusion: Suspicious diagnosis of epithelial ovarian cancer (subsequent histologically confirmation required); Plan to undergo a surgical procedure for the management of epithelial ovarian cancer or recurrent ovarian cancer previously treated with conventional treatment and involved in the trial as group A-D; ≥18 years old; ECOG Performance Status ≤ 2; Written informed consent; Indication for adnexectomy for a benign gynecological condition; ≥18 years old; ECOG Performance Status ≤ 2; Written informed consent.
Exclusion: Other active concomitant neoplasms that might confound the results of the planned analysis; Ongoing chronic treatment with steroids or other immune suppressive agents at the time of study entry; Ongoing active autoimmune disease requiring treatment or condition of immune deficiency.